Detalhe da pesquisa
1.
Sotatercept for the Treatment of Pulmonary Arterial Hypertension.
N Engl J Med
; 384(13): 1204-1215, 2021 04 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33789009
2.
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent ß-Thalassemia.
N Engl J Med
; 382(13): 1219-1231, 2020 03 26.
Artigo
Inglês
| MEDLINE | ID: mdl-32212518
3.
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.
N Engl J Med
; 382(2): 140-151, 2020 01 09.
Artigo
Inglês
| MEDLINE | ID: mdl-31914241
4.
Noninvasive diagnosis of chronic kidney diseases using urinary proteome analysis.
Nephrol Dial Transplant
; 32(12): 2079-2089, 2017 Dec 01.
Artigo
Inglês
| MEDLINE | ID: mdl-27984204
5.
Overcoming Barriers in Kidney Health-Forging a Platform for Innovation.
J Am Soc Nephrol
; 27(7): 1902-10, 2016 07.
Artigo
Inglês
| MEDLINE | ID: mdl-27127187
6.
Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl.
J Card Fail
; 20(12): 953-8, 2014 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-25307295
7.
Mechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl.
Am J Nephrol
; 39(6): 499-508, 2014.
Artigo
Inglês
| MEDLINE | ID: mdl-24903467
8.
Population Pharmacokinetics and Exposure-Response Relationship of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With ß-Thalassemia.
J Clin Pharmacol
; 61(1): 52-63, 2021 01.
Artigo
Inglês
| MEDLINE | ID: mdl-32696522
9.
Population Pharmacokinetics and Exposure-Response of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With Myelodysplastic Syndromes.
CPT Pharmacometrics Syst Pharmacol
; 9(7): 395-404, 2020 07.
Artigo
Inglês
| MEDLINE | ID: mdl-32602651
10.
Comparison of paricalcitol with maxacalcitol injection in Japanese hemodialysis patients with secondary hyperparathyroidism.
Ther Apher Dial
; 19(3): 225-34, 2015 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-25363733